MDM2 and neoplasm: Remaining tumours may have other aberrations in their p53 pathway, either p53 mutations (TP53Mut, 11-31% depending on subtype), or other changes in the downstream pathway that do not affect the level of MDM2 (MDM2Wt/TP53Wt, 11-88% depending on subtype) [4-6].